Advanced Biotherapy
Posted: Mon Nov 24, 2003 2:27 pm
Saw this while browsing today:
http://www.advancedbiotherapy.com/pages ... ed.html#m1
Multiple Sclerosis (MS)
back to Top
The Company sponsored two trials on 83 MS patients on the use of anti-cytokine therapy. The first was an open-label trial on patients with secondary progressive MS. Following promising results in this trial, a double-blind, placebo-controlled trial was conducted in a study design similar to that used in RA. The study compared anti-IFN-g and anti-Tumor Necrosis Factor-alpha (TNF-a) with placebo. Only patients with MS who received antibodies to IFN-g showed statistically significant improvement compared to the placebo group—a significant increase in the number of patients without confirmed disability progression. Positive clinical changes in this group at six months were supported by MRI data showing a decrease in the number of active enhancing lesions. After 12 months of follow-up, the anti-IFN-g patients still showed significant improvement relative to the placebo group on a number of endpoints, including disease progression and the number of active MRI lesions. Based on current reports from the National MS Society, over 400,000 Americans are afflicted with MS. 2.5 million are afflicted worldwide.
http://www.advancedbiotherapy.com/pages ... ed.html#m1
Multiple Sclerosis (MS)
back to Top
The Company sponsored two trials on 83 MS patients on the use of anti-cytokine therapy. The first was an open-label trial on patients with secondary progressive MS. Following promising results in this trial, a double-blind, placebo-controlled trial was conducted in a study design similar to that used in RA. The study compared anti-IFN-g and anti-Tumor Necrosis Factor-alpha (TNF-a) with placebo. Only patients with MS who received antibodies to IFN-g showed statistically significant improvement compared to the placebo group—a significant increase in the number of patients without confirmed disability progression. Positive clinical changes in this group at six months were supported by MRI data showing a decrease in the number of active enhancing lesions. After 12 months of follow-up, the anti-IFN-g patients still showed significant improvement relative to the placebo group on a number of endpoints, including disease progression and the number of active MRI lesions. Based on current reports from the National MS Society, over 400,000 Americans are afflicted with MS. 2.5 million are afflicted worldwide.